Verona Pharma Announces August 2021 Virtual Investor Conference Participation
27 juil. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
22 juil. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
10 juin 2021 02h00 HE
|
Verona Pharma plc
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and commercial milestone payments...
Verona Pharma to Present at Jefferies Virtual Healthcare Conference
25 mai 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference
04 mai 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 04, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
29 avr. 2021 02h00 HE
|
Verona Pharma plc
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and...
Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease
27 avr. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
23 avr. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
21 avr. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Lisa Deschamps Joins Verona Pharma as Non-Executive Director
02 mars 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...